Willing to return to enrolling medical site for all study assessments
Willingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose
Be willing to return to the center for all study-related follow up procedures, including blood collections and completion of imaging studies as required by the protocol
Patients with inability to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Willingness to return to Mayo Clinic for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Able to return for treatment and follow-up on the specified days
Willing to return to enrolling institution for follow-up or have a local physician willing to submit response and outcome data; Note: any and all therapy, potentially in its entirety, may be conducted outside of the Mayo Clinic
Must be willing to return to Mayo Clinic enrolling institution for follow-up.
Willingness to return to enrolling institution for follow-up
Patients with inability to return for follow-up visits to assess toxicity to therapy
Patients with known inability to return for follow-up visits or obtain follow-up studies required to assess for toxicity to therapy will be excluded
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to Mayo Clinic Rochester or another participating institution for follow-up; patients who are randomized to Arm B (cytotoxic chemotherapy) may receive chemotherapy at any oncology clinic able to provide the protocol-directed therapy and willing to send laboratory data to the participating institution; however, patients must be willing to return to the participating institution every two months for evaluation; patients who are randomized to Arm A must be willing to receive all treatment and follow-up at a participating institution
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to the enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Patients must be willing to receive follow-up care for a minimum of five years after treatment at the treating institution, including annual follow up visits; in the event that the patient is not from the local area and returning to the treating institution for follow up visits is too difficult, they must be willing to have their outside medical information (i.e. imaging studies, laboratory results and doctor or other health professional notes) released to the treating institution to track the results of treatment
Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Ability to attend required study visits and return for adequate follow up, as required by this protocol
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up during active monitoring phase of the study
Willing to return to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up for a minimum of 1 year
Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up
Patients who are unable to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy; telemedicine visits are acceptable
Willing to return to enrolling institution for follow-up during the Active Monitoring phase of the study\r\n* Note: the Active Monitoring phase of a study includes active treatment and observation
Willing to return to the enrolling institution for follow-up (during active treatment and active monitoring phase of the study)
Patient is willing to undergo treatment and monitoring at the enrolling institution
Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution
Willing to return to enrolling institution for follow-up
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Ability to return to Duke University Medical Center for adequate follow-up, as required by this protocol
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study [i.e. active treatment and observation])
Patients must be able to return to surgical facility for 30 and/or 90 day (+/- 20 days) follow up appointment
Willing to return to enrolling institution for follow-up
Willingness to return to the enrolling medical site for all study assessments
Willing to return to Mayo Clinic for follow-up
Willingness to return to the Mayo Clinic enrolling institution for follow-up
Willing to return to Mayo Clinic Rochester for follow-up
Willing to return for all required study assessments
Willing to return to Mayo Clinic enrolling institution for follow-up
Patients must be willing to receive follow-up care for a minimum of 5 years after treatment at participating institution(s) and annual visits unless it is too difficult to return to participating institution for follow-up care; in that event, patients must be willing to have outside medical information released in order to track the results of treatment
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictions
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Able to return for treatment and follow-up as specified in the protocol
Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Willing to return to enrolling institution for follow-up
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to Mayo Clinic enrolling institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to enrolling institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to Mayo Clinic in Rochester, Minnesota for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the treatment and observation phases of the study)
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Willing to return to enrolling institution for follow-up
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willingness to return to Mayo Clinic enrolling institution for follow-up
ARM A: Willingness to return to Mayo Clinic in Arizona for follow-up
ARM B: Willingness to return to Mayo Clinic in Arizona for follow-up
Willingness to return to Mayo Clinic Rochester for follow up
Willingness to return to enrolling institution for follow up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Patients must be willing to return to the clinic for follow-up visits
Willing to return to Mayo clinic for follow up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation
Willing to return to participating medical institutions for follow-up
Willing to return to Mayo Clinic for follow up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to Mayo Clinic for follow up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (active monitoring phase of the study); Note: During the active monitoring phase of a study (i.e., active treatment), participants must be willing to return to the consenting institution for follow-up
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Ability to attend required study visits and return for adequate follow up, as required by this protocol
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Agree to return for all follow-up evaluations and procedures specified in the protocol
Willing and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-up
Willing to return to consenting Mayo Clinic (Mayo Clinicâ€™s campus in Rochester), for follow-up during the Active Monitoring Phase of the study
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Willing to return to consenting institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to Mayo Clinic Rochester for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to Mayo Clinic Rochester for follow-up appointments
Willingness to return to University of Maryland Greenebaum Cancer Center (UMGCC) or other participating institutions for treatment and follow-up
Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willing to return to Mayo Clinic Rochester for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, Mayo Clinic Florida for treatment\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-up
Ability to return to Duke University Medical Center for adequate follow-up as required by this protocol
Willing to return to consenting Mayo Clinic institution for follow-up during the Active Monitoring Phase of the study; Note: during the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willingness to return to Mayo Clinic Rochester for follow-up, except for some appointments that can be made with the local physician
Willingness to return to Mayo Clinic
Ability to provide informed consent, and to return to clinic for adequate follow-up for the period that the protocol requires
The subject must be willing to return to the study center for vaccinations and study-related follow up procedures including blood and tumor collections and completion of imaging studies as required by the protocol.
Willingness to return to Mayo Clinic Rochester for follow-up
Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity and response to therapy
Willing to return to Mayo Clinic, Rochester during the observation phase
Patients who are unable to return for follow-up visits as required by this study
Willingness to return to a lymphoma Specialized Program of Research Excellence (SPORE) enrolling institution for follow-up
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
NON-PROGRESSED DIPG (STRATUM 2): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willingness to return to Mayo Clinic for follow up
Agreement to return for the trial required follow-up visits
Willing to return to Mayo Clinic enrolling institution for follow-up
Willing to return to consenting institution for follow-up during the study
Willing to return to enrolling institution for follow-up
Willing to return to enrolling institution (Mayo Clinic in Arizona) for follow-up and all study treatments
Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Willing to return to Alliance enrolling institution for follow-up
Willingness to return to the Alliance enrolling institution for follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to an Academic and Community Cancer Research United (ACCRU) enrolling institution for follow-up (i.e., active monitoring, which includes active treatment and observation)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
After the week-long study treatment, participants must be willing to return to the enrolling institution for a follow-up visit
Willing to return to enrolling institution for follow-up of the study and optional crossover (if applicable)
Willing to return to an Alliance enrolling institution for follow-up
Willing to work with the enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Patient must still be in active follow-up: seen for a follow-up visit in the participating center at least once in the 3 years prior to enrollment and/or scheduled to be seen for follow-up in the next 6 months (i.e. in active follow-up)
Willingness to return to the enrolling institution for follow-up
Willing to return mail-in questionnaires during the observation phase of the study
Willing to use and return the technology provided by the study
Willing to undergo monthly follow-up assessment, either in person at the enrolling institution or by telephone
Willingness to return to the enrolling site for the study surgical procedures, including pre-operative and post-operative care; (patients in the ISDO arm must be willing to return to the enrolling site for yearly ovarian cancer assessment)
Agrees to return to participating institution for 3 HPV vaccine injections
Unable to return for follow-up visits and tests
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study; patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution
Willingness to return to the enrolling site for ovarian cancer screening during the study period
Return for follow-up visits
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\r\n* Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
Patients must be willing to return to National Institutes of Health (NIH) for follow-up
